Sebastián Seni-Molina

Sebastián Seni-Molina

Auto-generated profile, based on publicly available information

Sebastián Seni-Molina

Fundación Valle del Lili

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2025 in Global Heart
Verified
Journal Article
Open access
PDF file
ASAlex David Sotomayor-Julio
Alex David Sotomayor-Julio
SSSebastián Seni-Molina
Sebastián Seni-Molina
JGJuliana María Gutiérrez-Posso
Juliana María Gutiérrez-Posso
JMJuan Andrés Muñoz-Ordoñez
Juan Andrés Muñoz-Ordoñez
VAValeria Azcárate-Rodríguez
Valeria Azcárate-Rodríguez
OGOn Behalf of AMERICCAASS Research Group
On Behalf of AMERICCAASS Research Group
Introduction: Heart failure (HF) is a leading cause of hospitalization and mortality worldwide, emphasizing the critical role of optimal medical therapy (OMT) in improving patient outcomes. Despite extensive research, most scientific evidence regarding HF is gathered and studied in developed countries, leaving substantial knowledge gaps regarding HF in Latin America and the Caribbean. Objective: To characterize the sociodemographic and clinical profiles of HF patients and to assess their adherence to OMT in the Americas. Methods: The AMERICCAASS Registry is a prospective, observational, multicenter study, including patients aged 18 and older, both hospitalized and ambulatory, and diagnosed with HF. Sociodemographic and clinical data were collected from the first 2,500 patients to characterize the study population. Adherence to OMT was subsequently evaluated according to left ventricular ejection fraction (LVEF). Results: Among the 2,500 patients in the study, 36% were hospitalized and 64% were ambulatory. The median ages of the patients were 66.9 (hospitalized) and 66.3 years (ambulatory). Males made up 60.8% of hospitalized and 59.3% of ambulatory patients. The majority had HF with reduced LVEF (≤40%): 60.7% for hospitalized and 58.5% for ambulatory. The New York Heart Association (NYHA) functional class II predominated among ambulatory patients (67.9%), while NYHA functional class III predominated among hospitalized patients (46.6%). Only 21% of patients with reduced LVEF were receiving quadruple therapy, whereas 12.3% of patients with mildly reduced LVEF (41–49%) were on this treatment. Conclusion: The findings demonstrate that the sociodemographic and clinical profiles of HF patients in the Americas are broadly consistent with international reports. However, the low use of OMT observed in this population underscores gaps in adherence to current guidelines. These results highlight the need for targeted strategies to improve pharmacological treatment adherence to optimize health outcomes in this region.

2 September 2025 in Lipids in Health and Disease
Verified
Journal Article
Open access
PDF file
BCBrayan Daniel Cordoba-Melo
Brayan Daniel Cordoba-Melo
SSSebastián Seni-Molina
Sebastián Seni-Molina
JAJuan Pablo Arango-Ibanez
Juan Pablo Arango-Ibanez
MAMilton René Ayala
Milton René Ayala
JTJosé Fidel Tatis-Méndez
José Fidel Tatis-Méndez
OGOn Behalf of EDHIPO MARCA Research Group
On Behalf of EDHIPO MARCA Research Group
Cardiovascular disease remains the leading cause of morbidity and mortality worldwide, with dyslipidemia playing a key role in its progression. Despite advances in lipid-lowering therapy (LLT), LDL-C (Low-Density Lipoprotein Cholesterol) goal achievement remains suboptimal. This study evaluated LDL-C goal attainment in Colombian patients with very high cardiovascular risk (CVR) due to coronary artery disease (CAD) following ESC/EAS guidelines updates. EDHIPO MARCA (Evaluación De adherencia a la terapia HIPOlipemiante en pacientes de Muy Alto Riesgo CArdiovascular) is a retrospective, multicenter study assessing LDL-C goal achievement in patients with CAD. Data were collected from previous coronary angiogram reports and medical records across 11 Colombian healthcare institutions with certified interventional cardiology services. Patients with CAD who had at least one follow-up LDL-C measurement and an LLT prescription within 12 months post-angiogram were included. LDL-C goal attainment was assessed across three periods—2011–2012, 2016–2017, and 2021–2022—corresponding to the updates of ESC/EAS guidelines (2011, 2016, and 2019, respectively). The LDL-C goals were <70 mg/dL for the first two periods and <55 mg/dL for the most recent one. LDL-C was measured or estimated using the Friedewald equation. Descriptive analyses were performed. A total of 1,788 patients were included, with a median age of 66 years (IQR: 59–74), and 70.7% were male. Hypertension (67.5%) and overweight (40.8%) were the most common comorbidities. At discharge, statins were prescribed in 84.1% (95% CI: 82.4–85.8%) of patients, increasing to 99.1% (95% CI: 98.6–99.5%) at the end of follow-up (median 6.8 months); PCSK9 inhibitors were prescribed in 1.5%, exclusively in 2019. At the end of follow-up, 36.6% (95% CI: 34.3%, 38.8%) achieved LDL-C goals. By guideline period, goal attainment was 12.1% (95% CI: 5.4%, 18.8%) in 2011, 42.3% (95% CI: 37.9%, 46.8%) in 2016, and 36.2% (95% CI: 33.5%, 38.9%) in 2019. By number of follow-ups, LDL-C goal achievement increased from 32.9% (1 follow-up) to 44.0% (4 follow-ups). Despite widespread LLT use, LDL-C target achievement remains suboptimal. Frequent follow-up and greater use of combination therapy beyond statins may be essential to improve lipid control in very high CVR patients.

5 May 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
JAJuan Pablo Arango‐Ibanez
Juan Pablo Arango‐Ibanez
SSSebastián Seni‐Molina
Sebastián Seni‐Molina
JMJuan Andrés Muñoz-Ordoñez
Juan Andrés Muñoz-Ordoñez
VAValeria Azcárate‐Rodríguez
Valeria Azcárate‐Rodríguez
AVAndrea Valencia‐Orozco
Andrea Valencia‐Orozco
SMSebastian Seni Molina
Sebastian Seni Molina
Background: Acute heart failure (HF) frequently coexists with multimorbidity. Comorbidity clusters have been associated with distinct clinical outcomes, but data from the Americas remain limited. We aimed to identify comorbidity clusters in patients with acute HF and assess their association with in‐hospital outcomes. Methods: This cohort study applied latent class analysis to patients from the AMERICCAASS Registry (Registro Americano de Insuficiencia Cardiaca Ambulatoria o Agudamente descompensada). Adjusted Poisson regression assessed in‐hospital mortality and intensive care unit (ICU) admission, and multivariable analysis identified independent predictors of ICU admission. Results: Among 1638 patients, 60.6% were men and the median age was 67.2 years. Hypertension (69.4%), smoking (40.3%), and coronary artery disease (33.8%) were common comorbidities. Cluster 1 (Young, n=828) included the youngest patients (median age 63.2 years) with the fewest comorbidities. Cluster 2 (Cardio‐Kidney‐Metabolic, n=512) represented the oldest group (median age 71.8 years) with the highest median body mass index (27.7 kg/m 2 ), the greatest proportion of HF with mildly reduced or preserved ejection fraction (44.7%), and a high comorbidity burden. Cluster 3 (“Ischemic,” n=298) was characterized by older patients (median age 70.2 years) with an exceptionally high prevalence of coronary artery disease (96.3%) and the greatest proportion of HF with reduced ejection fraction (61.4%). ICU admission risk was higher in Cluster 2 (adjusted risk ratio [aRR], 1.15 [95% CI, 1.03–1.27]; P =0.009) and Cluster 3 (aRR, 1.25 [95% CI, 1.12–1.39]; P <0.001), compared with Cluster 1. Severe valvular insufficiency, peripheral artery disease, dyslipidemia, cancer, acute coronary syndrome, anemia, and cardiogenic shock were associated with higher ICU admission risk. Conclusions: Patients with acute HF in the Americas exhibit distinct comorbidity patterns associated with different clinical profiles and ICU admission rates, which may inform risk stratification and management strategies. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT05295641.

1 December 2025 in Cardiology Research
Verified
Journal Article
Open access
PDF file
Juan David Peláez-MartínezJuan David Peláez-Martínez
Juan David Peláez-Martínez
DCDaniel Castillo
Daniel Castillo
JMJackelin Mainguez
Jackelin Mainguez
SSSebastian Seni-Molina
Sebastian Seni-Molina
YRYorlany Rodas
Yorlany Rodas
JGJuan Esteban Gómez-Mesa
Juan Esteban Gómez-Mesa
Background: Heart failure (HF) is a major cause of global morbidity and mortality. Patients with acute decompensated chronic HF (ad-CHF) usually have more comorbidities, whereas those with de novo acute HF (dn-AHF) may have a more severe clinical presentation. Despite extensive research on HF, comparative data on in-hospital outcomes and mortality between these groups are scarce in Latin American countries. The aim of this study was to evaluate differences in in-hospital complications and mortality among patients hospitalized with either dn-AHF or ad-CHF. Methods: An ambispective study was conducted at a tertiary hospital in Colombia, including 780 patients hospitalized for acute HF. Patients were classified as dn-AHF or ad-CHF, and sociodemographic, clinical, and in-hospital outcomes were compared using bivariate analysis. A Firth penalized logistic regression model was used to assess the association between dn-AHF and in-hospital mortality. Results: Of these patients, 39.2% had dn-AHF, and 60.8% had ad-CHF. Median ages were 67 (interquartile range (IQR): 56 - 76) and 66 (IQR: 55 - 79) years, respectively. Both groups had a predominance of reduced left ventricular ejection fraction, with median values of 30% in ad-CHF and 34% in dn-AHF. Ad-CHF patients had more comorbidities, whereas dn-AHF patients showed higher rates of cardiac and non-cardiac complications. Intensive care unit (ICU) admission rates were similar, the need for invasive mechanical ventilation (P < 0.001) and the occurrence of infections (P = 0.049) were significantly more frequent in patients with dn-AHF. In-hospital mortality was higher in dn-AHF than ad-CHF (9.8% vs. 5.5%, P = 0.023). After adjustment, dn-AHF remained independently associated with greater in-hospital mortality (odds ratio (OR): 1.87; 95% confidence interval (CI): 1.07 - 3.31; P = 0.029). Conclusions: Patients with dn-AHF experienced more in-hospital complications and higher mortality than those with ad-CHF, despite similar ICU admission rates and fewer comorbidities. These results highlight the prognostic importance of dn-AHF and underscore the need for early identification, vigilant monitoring, and phenotype-specific management from admission to improve outcomes, particularly among patients with reduced ejection fraction.

1 January 2025 in Case Reports in Medicine
Verified
Journal Article
Open access
ASAlex David Sotomayor-Julio
Alex David Sotomayor-Julio
AGAndrea Facio-Lince García
Andrea Facio-Lince García
WBWikler Bernal-Torres
Wikler Bernal-Torres
SSSebastián Seni-Molina
Sebastián Seni-Molina
JLJuan David Lopez
Juan David Lopez
Background: Dilated cardiomyopathy is a leading cause of heart failure and heart transplantation. Among its etiologies, genetic variants account for up to 35% of cases. Variants in the FLNC gene have gained recognition due to their association with a higher risk of major ventricular arrhythmias and sudden cardiac death. Early identification and intervention are critical to improving patient outcomes. Case Presentation: We present the case of a 28‐year‐old male with no cardiovascular history who presented with ischemic stroke. Neurological improvement was noted following thrombolysis. Extensive testing ruled out infectious, thrombotic, and autoimmune causes. Subsequent evaluation revealed severe left ventricular systolic dysfunction (ejection fraction of 20%) and biventricular dilated cardiomyopathy. Genetic testing identified a likely pathogenic FLNC variant NM_001458.5(FLNC):c.1156G>T; p.Glu386∗, confirming the diagnosis of FLNC ‐associated dilated cardiomyopathy. Discussion: This case highlights the importance of investigating genetic causes in young patients presenting with unexplained dilated cardiomyopathy. Although truncating FLNC mutations are rare, they are associated with adverse outcomes, including major ventricular arrhythmias and sudden cardiac death. Atypical biventricular involvement suggests overlapping phenotypes, complicating the diagnostic process. Advanced imaging modalities, comprehensive management strategies, and early genetic testing are crucial to optimizing patient outcomes.

17 November 2026 in Clinical Cardiology
Verified
Journal Article
Open access
SSSebastián Seni‐Molina
Sebastián Seni‐Molina
Juan David Peláez-MartínezJuan David Peláez-Martínez
Juan David Peláez-Martínez
JLJhon López
Jhon López
VMValentina Morales‐Arias
Valentina Morales‐Arias
JGJuliana María Gutiérrez‐Posso
Juliana María Gutiérrez‐Posso
JGJuan Esteban Gómez-Mesa
Juan Esteban Gómez-Mesa
Background: Heart failure (HF) is a major global health concern, and dyskalemias are common and associated with adverse outcomes. However, evidence from the Americas, particularly Latin America and the Caribbean, remains limited. Objective: To evaluate the association between admission dyskalemias and in‐hospital mortality in hospitalized patients with HF across the Americas. Methods: This subanalysis of the AMERICCAASS Registry included hospitalized patients with HF with available admission serum potassium and documented discharge status. Patients were classified as hypokalemic (< 3.5 mmol/L), normokalemic (3.5–4.9 mmol/L), or hyperkalemic (≥ 5.0 mmol/L). In‐hospital mortality was assessed using Poisson regression and propensity score overlap weighting. Results: Among 1541 patients, 12.5% had hypokalemia, 75.6% normokalemia, and 11.9% hyperkalemia. Median age was 68 years, and 60.6% were male. Chronic kidney disease was more frequent in hyperkalemia (30.4%), whereas atrial fibrillation was more frequent in hypokalemia (30.7%). Dyskalemic patients more often presented with hypoperfusion profiles and higher New York Heart Association class. In the propensity score overlap‐weighted analysis, hyperkalemia was associated with higher in‐hospital mortality (aRR 1.81; 95% CI 1.10–2.97; p = 0.019), whereas no statistically significant association was detected for hypokalemia (aRR 1.43; 95% CI 0.79–2.60; p = 0.237). Conclusion: Admission hyperkalemia was associated with higher in‐hospital mortality among hospitalized patients with HF across the Americas. Given the observational design, hyperkalemia should be interpreted primarily as a marker of greater disease severity and short‐term clinical vulnerability rather than as a direct causal determinant of mortality.